Literature DB >> 225441

Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice.

C J Gauntt, M D Trousdale, D R LaBadie, R E Paque, T Nealon.   

Abstract

Inoculation of adolescent CD-1 mice with one variant of coxsackievirus B3 (CVB3m) results in induction of readily observable myocardial lesions, whereas inoculation of siblings with a second variant (CVB3o) results in little or no myocarditis. These variants could not be distinquished from each other on the basis of replication properties in HeLa cells or cardiac tissues in vivo, sensitivity to human interferon in HeLa cells, induction of interferon in the mouse, generation of detectable levels of defective-interfering particles in HeLa cells or in cardiac tissue in vivo, stimulation of serum-neutralizing antibody titers, nor in their rate of clearance by the spleen. Infectivity of CVB3o was slightly more heat labile at 34 degrees C than CVB3m. Little if any replication of either CVB3o or CVB3m occurred in either adherent or nonadherent populations of normal murine lymphoid cells. Cardiac tissues from mice inoculated with CVB3m but not CVBo contain new antigens that can inhibit migration of sensitized lymphocytes from CVB3m-immunized mice in an in vitro cell-migration-inhibition assay. However, the CVB3o variant was shown to have the genetic capability of inducing myocarditis if the mice were treated with cyclophosphamide prior to virus inoculation. These results suggest, in agreement with our previously published work, that induction of myocarditis by CVB3 requires destruction of myocytes by virus and subsequent stimulation of cell-mediated responses to new antigens produced in the myocardium during virus replication.

Entities:  

Mesh:

Year:  1979        PMID: 225441     DOI: 10.1002/jmv.1890030307

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  48 in total

Review 1.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 2.  Coxsackievirus infection as a trigger of cardiac autoimmunity.

Authors:  L J Wolfgram; N R Rose
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

4.  Antigen-specific suppressor T cells prevent cardiac injury in Balb/c mice infected with a nonmyocarditic variant of coxsackievirus group B, type 3.

Authors:  M Estrin; C Smith; S Huber
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

Review 5.  Role of cytotoxic T cells in experimental myocarditis.

Authors:  N Van Houten; S A Huber
Journal:  Springer Semin Immunopathol       Date:  1989

6.  Derivation and characterization of an efficiently myocarditic reovirus variant.

Authors:  B Sherry; F J Schoen; E Wenske; B N Fields
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Selection of an attenuated Coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen.

Authors:  N Van Houten; P E Bouchard; A Moraska; S A Huber
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.

Authors:  N M Chapman; Z Tu; S Tracy; C J Gauntt
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.

Authors:  C J Gauntt; R E Paque; M D Trousdale; R J Gudvangen; D T Barr; G J Lipotich; T J Nealon; P S Duffey
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.